These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32047277)

  • 1. Approvals in 2019: international review and a new agnostic molecular entity.
    Singh H; Blumenthal G; Pazdur R
    Nat Rev Clin Oncol; 2020 Mar; 17(3):130-131. PubMed ID: 32047277
    [No Abstract]   [Full Text] [Related]  

  • 2. Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.
    Blumenthal GM; Pazdur R
    Nat Rev Clin Oncol; 2019 Mar; 16(3):139-141. PubMed ID: 30670830
    [No Abstract]   [Full Text] [Related]  

  • 3. New drug approvals in oncology.
    Kurzrock R; Kantarjian HM; Kesselheim AS; Sigal EV
    Nat Rev Clin Oncol; 2020 Mar; 17(3):140-146. PubMed ID: 32020042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
    Seligson ND; Knepper TC; Ragg S; Walko CM
    Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
    Amiri-Kordestani L; Pazdur R
    Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs, diagnostic tests approved quickly.
    Rose S
    Cancer Discov; 2011 Oct; 1(5):371. PubMed ID: 22586620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in oncology come of age.
    Klein A
    Clin Ther; 2013 Sep; 35(9):1256-7. PubMed ID: 24054702
    [No Abstract]   [Full Text] [Related]  

  • 8. Tissue-agnostic cancer drug pipeline grows, despite doubts.
    Garber K
    Nat Rev Drug Discov; 2018 Apr; 17(4):227-229. PubMed ID: 29520093
    [No Abstract]   [Full Text] [Related]  

  • 9. Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies.
    Peng Y; Tao H; Gao Y; Yang Y; Chen Z
    Curr Top Med Chem; 2021; 21(5):404-425. PubMed ID: 32543358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inappropriate use of progression-free survival in cancer drug approvals.
    Naci H; Davis C
    BMJ; 2020 Mar; 368():m770. PubMed ID: 32156802
    [No Abstract]   [Full Text] [Related]  

  • 11. 2011 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
    Khozin S; Liu K; Jarow JP; Pazdur R
    Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
    [No Abstract]   [Full Text] [Related]  

  • 13. Agnostic drug development revisited.
    Hernando-Calvo A; Rossi A; Vieito M; Voest E; Garralda E
    Cancer Treat Rev; 2024 Jul; 128():102747. PubMed ID: 38763053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
    Hierro C; Matos I; Martin-Liberal J; Ochoa de Olza M; Garralda E
    Clin Cancer Res; 2019 Jun; 25(11):3210-3219. PubMed ID: 30670489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another.
    Tao D; Schott S; Prasad V
    Am J Med; 2019 Mar; 132(3):e509-e511. PubMed ID: 30201241
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges ahead for companion diagnostics.
    Schmidt C
    J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA releases tissue-agnostic cancer drug draft guidance.
    Mullard A
    Nat Rev Drug Discov; 2022 Dec; 21(12):868. PubMed ID: 36333480
    [No Abstract]   [Full Text] [Related]  

  • 19. New Clinical Trial Designs Hasten Approvals for Targeted Therapies.
    Schmidt C
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26944760
    [No Abstract]   [Full Text] [Related]  

  • 20. Consortium Outlines 3 Solutions to Maximize the Benefit and Affordability of Targeted Cancer Drugs.
    Cancer; 2018 Aug; 124(16):3283. PubMed ID: 30141838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.